Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

作者: Limei Fan , Muyou Tian , Yunyi Liu , Ying Deng , Zhengkai Liao

DOI: 10.18632/ONCOTARGET.16161

关键词:

摘要: // Limei Fan 1, 2, * , Muyou Tian 3, Yunyi Liu Ying Deng 2 Zhengkai Liao 4 Jinhua Xu 1 School of Medicine, Jianghan University, Wuhan, Hubei 430056, China Key Laboratory Optoelectronic Chemical Materials and Devices, Ministry Education, 3 Department Radiation Medical Oncology, Zhongnan Hospital, Wuhan 430071, Tumor Biological Behavior, These authors contributed equally to this work Correspondence to: Liu, email: liuyy1987@jhun.edu.cn Liao, zliao@whu.edu.cn Xu, xu5520@gmail.com Keywords: TNBC, Cu(sal)(phen), cell growth, apoptosis, anti-apoptotic protein Received: December 20, 2016      Accepted: March 03, 2017      Published: 13, 2017 ABSTRACT In study, we investigated anti-tumor activity associated molecular mechanism action Salicylate ●Phenanthroline Copper (II) Complex in triple-negative breast cancer. inhibited the growth four cancer lines (MCF-7, T47D, MDA-MB-231 BT-20) induced apoptosis a concentration-dependent manner. The effect was more profound BT-20 lines. Western blot showed that expression apoptosis-related Bcl-2, Bcl-xl survivin significantly reduced after treatment with Complex. vivo administration attenuated tumor xenografts, levels Bcl-xL were as measured by immunohistochemical staining. data suggest is promising novel therapeutic drug for warrants further study.

参考文章(35)
Gerard I. Evan, Karen H. Vousden, Proliferation, cell cycle and apoptosis in cancer Nature. ,vol. 411, pp. 342- 348 ,(2001) , 10.1038/35077213
Sibylle Loibl, Carsten Denkert, Gunter von Minckwitz, Neoadjuvant treatment of breast cancer--Clinical and research perspective. The Breast. ,vol. 24, ,(2015) , 10.1016/J.BREAST.2015.07.018
Giuseppe Palma, Giuseppe Frasci, Andrea Chirico, Emanuela Esposito, Claudio Siani, Carmela Saturnino, Claudio Arra, Gennaro Ciliberto, Antonio Giordano, Massimiliano D’Aiuto, Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. ,vol. 6, pp. 26560- 26574 ,(2015) , 10.18632/ONCOTARGET.5306
Inflammatory diseases and copper. Journal of the Royal Society of Medicine. ,vol. 77, pp. 256- ,(1982) , 10.1007/978-1-4612-5829-2
Jinhua Xu, Yinghua Chen, Dezheng Huo, Andrey Khramtsov, Galina Khramtsova, Chunling Zhang, Kathleen H. Goss, Olufunmilayo I. Olopade, β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Molecular Carcinogenesis. ,vol. 55, pp. 431- 439 ,(2016) , 10.1002/MC.22292
Ander Urruticoechea, Ian E. Smith, Mitch Dowsett, Proliferation Marker Ki-67 in Early Breast Cancer Journal of Clinical Oncology. ,vol. 23, pp. 7212- 7220 ,(2005) , 10.1200/JCO.2005.07.501
Fausto Petrelli, Andrea Coinu, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Veronica Lonati, Sandro Barni, The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis Breast Cancer Research and Treatment. ,vol. 144, pp. 223- 232 ,(2014) , 10.1007/S10549-014-2876-Z
Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni, Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology. ,vol. 7, pp. 683- 692 ,(2010) , 10.1038/NRCLINONC.2010.154
Rosalia de Necochea-Campion, Chien-Shing Chen, Saied Mirshahidi, Frank D. Howard, Nathan R. Wall, Clinico-pathologic relevance of Survivin splice variant expression in cancer Cancer Letters. ,vol. 339, pp. 167- 174 ,(2013) , 10.1016/J.CANLET.2013.06.007